The analysis of the drug supply system for patients with bronchial asthma in the Republic of Tatarstan

Aim. To analyze the current drug supply system for patients with bronchial asthma in the Republic of Tatarstan. Methods. Systematic, marketing, statistical, retrospective, situational analysis was performed. Bronchial asthma incidence data, data of drug supply system for patients with bronchial asthma in the Republic of Tatarstan were analyzed. Results. From 2005 to 2011 the number of patients with a diagnosis of bronchial asthma has increased by 23.9%, and there were 25 700 newly diagnosed cases. Out of 215 medications to treat bronchial asthma registered in the country, 68 are produced in Russia. The rate of inhaled medications produced by domestic is only 15.91%. Outpatients are provided with drugs under the federal and regional programs of preferential drug supply. In 2010 - over 81 thousand, in 2011 - over 87 thousand of prescriptions were issued under the program of vital drug supply for patients with bronchial asthma. The cost of drug supply exceeded 60 million rubles in 2010, in 2011 it was about 67 million rubles. There was a 5.87% increase of number of patients covered by drug supply in 2010-2011. If the patient denies the drug supply, he/she is responsible to pay for his medication, the approximate cost of treatment of patient with bronchial asthma is over 28 000 rubles per year. In 2011 the number of patients supplied under the regional supply program has significantly increased by 76.29% leading to decrease of cost of medications supplied per 1 patient. Conclusions. The need to find evidence-based solutions to the problems of drug supply system for patients with bronchial asthma at the regional level was identified.

bronchial asthma, incidence, assortment analysis, drug supply system